Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) had its price target reduced by stock analysts at Needham & Company LLC from $43.00 to $36.00 in a report issued on Tuesday. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 9.09% from the company’s current price.

Several other brokerages have also issued reports on BHVN. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. BidaskClub upgraded shares of Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 28th. Morgan Stanley increased their price target on shares of Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the stock an “overweight” rating in a research note on Monday, September 25th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $54.00 price target on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, September 12th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Biohaven Pharmaceutical Holding Co has a consensus rating of “Buy” and an average price target of $40.80.

Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) opened at 33.00 on Tuesday. The stock’s 50 day moving average is $35.62 and its 200-day moving average is $27.71. Biohaven Pharmaceutical Holding Co has a one year low of $17.00 and a one year high of $39.51. The firm’s market capitalization is $1.19 billion.

COPYRIGHT VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Price Target Cut to $36.00” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/05/biohaven-pharmaceutical-holding-co-ltd-bhvn-price-target-cut-to-36-00.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.